Clinical Trials Browser

Phase 2 × Tuberous Sclerosis × 1 year × Clear all

Epilepsy, Tuberous Sclerosis

NCT05626634 2025-12-03

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Phase 2 Completed

41 enrolled

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT03363763 2025-12-01

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Phase 2 Terminated

24 enrolled 11 charts

Erythema, Exanthema, Fibroma, Tuberous Sclerosis, Facies

NCT06081348 2025-07-16

CALM

Phase 2 Recruiting

130 enrolled

Autism Spectrum Disorder, Anxiety Disorders, Attention Deficit Disorder with Hyperactivity, Autistic Disorder, DiGeorge Syndrome, Fragile X Syndrome, Tourette Syndrome, Tic Disorders, Tuberous Sclerosis, 22q11 Deletion Syndrome, Neurodevelopmental Disorders

NCT05059327 2025-06-04

Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

Phase 2 Completed

61 enrolled

Seizures, Tuberous Sclerosis

Clinical Trials

TSC-STEPS

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

CALM

Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC